Bringing light to basal cell carcinoma therapy
 




Vision
About Us
Contact
Photometics has developed a uniquely effective therapy for Basal Cell Carcinoma, the most common form of skin cancer, affecting more than 1 million Americans annually.

Photometic's patented "selective photo-apoptosis" technology is based on decades of research into differential infrared absorption, determining and delivering the precise characteristics of light energy needed to kill cancer cells while leaving surrounding tissues intact.
Photometics Logo